Breaking Through Cancer Pain: From Single-Drug Management to Multimodal Analgesia

Cancer pain affects 60%-80% of patients with advanced cancer, and approximately 30% of patients experience inadequate pain control. Although the World Health Organization (WHO) three-step analgesic ladder has substantially improved pain management, inadequate analgesia, opioid-related adverse effects, and refractory pain continue to pose significant clinical challenges.

This narrative review critically evaluates recent advances in cancer pain management, including novel analgesics, optimized opioid formulations, nanomedicine, invasive interventions (intrathecal drug delivery, neuromodulation, and neurolysis), and complementary integrative therapies, aiming to provide up-to-date insights for clinicians and researchers.

Novel analgesics targeting μ-opioid receptor bias, ion channels, and multitarget strategies have shown preclinical promise. Improved opioid formulations and nanomedicine-based approaches may enhance drug delivery and reduce toxicity. Fourth-step interventions, including intrathecal drug delivery, neuromodulation, and neurolysis, provide targeted options for selected patients with refractory cancer pain. Integrative therapies, including mind-body interventions, acupuncture, massage, music therapy, and game-based approaches, may improve symptom burden and quality of life, although evidence for direct analgesic effects remains limited.

Cancer pain management is evolving toward a multimodal and increasingly personalized framework. Despite substantial progress, many emerging therapies lack robust cancer-specific validation. High-quality clinical trials, standardized treatment protocols, and improved translational strategies are needed to establish evidence-based precision cancer pain management.